The history of myeloproliferative disorders: before and after Dameshek.
about
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1JAK and MPL mutations in myeloid malignancies.Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersOne thousand patients with primary myelofibrosis: the mayo clinic experience.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Quantitative analyses of myelofibrosis by determining hydroxyproline.Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice.Treatment options for essential thrombocythemia and polycythemia vera.Molecular classification of myeloproliferative neoplasms-pros and cons.How common are myeloproliferative neoplasms? A systematic review and meta-analysis.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Thrombotic risk correlates with mutational status in true essential thrombocythemia.Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.Highlights of 2008 in bone marrow biopsy pathology.Primary myelofibrosis and the "bad seeds in bad soil" concept.Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
P2860
Q27687464-395277E2-C7FE-40FD-A3BC-149521C109E1Q33378737-47251392-A80F-4ED8-8CC3-2755E6FFE308Q33921220-6CB21D7C-01C4-4BAC-94EA-3F39E2DFE85EQ36374813-7499A861-AB75-4F5A-86B6-723E32B91EE4Q36512816-A2C65EFF-CBFE-4D38-893C-92CDE5FF6BE8Q36782943-811F1E2C-5F64-43CD-843F-B66ADBFA8334Q37044050-78BF57E9-D57D-44CD-8C77-8EC05B5299FAQ37189322-9CD5A949-D75F-450D-9CB1-3C408A6848C5Q37379320-C126DA07-D216-427E-8B50-5F918A11455EQ37555790-CC2084A3-1513-4609-A8BF-66398F7FD57CQ37715790-903B8BF2-0CCF-4579-96EB-44ACC60FA8A8Q37810107-6EDFE4A7-22E2-4F0D-9D6D-9267735A9E0AQ38148982-CFD0E06D-224F-4F6B-A903-7AB80A539AC7Q38223791-B3DAE4B4-C8D1-4F66-B64B-C5A1B55D0CF3Q38569146-3138DB8A-4AF7-45D0-9B85-A921AE69D9E4Q39704198-655F60C5-939A-4061-A9B3-064FF25F87EAQ40298579-16B20CE8-0B3C-4485-AA7B-526CF09190CAQ41808980-F61A3719-8591-4820-9ED6-82CFD215C999Q41838687-2520F36F-EF05-47B7-9290-F51C4149355AQ42671679-B8C9CDD8-28B7-4A08-92E1-815625626AC0Q42870230-D400517C-AD1E-4D5B-8421-073559FF6A30Q43122604-11712366-CA8A-40E8-BDB1-57CBC9568D4AQ47805850-9E82EDF2-2DE2-4B17-8BB0-06B72238116FQ48509408-1D887F87-ACEA-4186-99E0-C72F4343EF37Q54400499-8156AFA7-0FB9-4F75-B553-3C9D9529B9D1
P2860
The history of myeloproliferative disorders: before and after Dameshek.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The history of myeloproliferative disorders: before and after Dameshek.
@en
type
label
The history of myeloproliferative disorders: before and after Dameshek.
@en
prefLabel
The history of myeloproliferative disorders: before and after Dameshek.
@en
P2860
P356
P1433
P1476
The history of myeloproliferative disorders: before and after Dameshek.
@en
P2860
P2888
P356
10.1038/SJ.LEU.2404946
P577
2007-09-20T00:00:00Z